Detalhe da pesquisa
1.
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
Blood
; 137(8): 1019-1023, 2021 02 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33167024
2.
Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort.
Ann Hematol
; 100(4): 987-993, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33495922
3.
First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study.
Hematol Oncol
; 35(4): 671-678, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27878835
4.
Late-Onset Progressive Multifocal Leukoencephalopathy (PML) and Lymphoma in a 65-Year-Old Patient with XIAP Deficiency.
J Clin Immunol
; 41(8): 1975-1978, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34580798
5.
Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.
Blood
; 119(22): 5104-10, 2012 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-22337714
6.
Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO group.
Am J Hematol
; 94(7): E183-E185, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30945328
7.
Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia.
Haematologica
; 103(7): e304-e306, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29545348
8.
Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study.
Haematologica
; 103(8): e356-e359, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29519866
9.
Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia.
J Clin Oncol
; 41(14): 2607-2616, 2023 05 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36763945
10.
Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia.
Blood Adv
; 5(9): 2438-2446, 2021 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33961019
11.
High incidence of atrial fibrillation in patients treated with ibrutinib.
Open Heart
; 6(1): e001049, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31168393
12.
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
Lancet Haematol
; 6(9): e470-e479, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31324600
13.
Overview of monoclonal B-cell lymphocytosis.
Br J Haematol
; 139(5): 701-8, 2007 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-18021084
14.
A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone.
Leuk Lymphoma
; 58(11): 2615-2623, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28395585
15.
Patients' Non-Medical Characteristics Contribute to Collective Medical Decision-Making at Multidisciplinary Oncological Team Meetings.
PLoS One
; 11(5): e0154969, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27167521
16.
Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia.
Leuk Lymphoma
; 57(2): 328-334, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26140301
17.
Drug-induced eosinophilia and systemic symptoms: hypersensitivity or peripheral T-cell lymphoma?
Arch Dermatol
; 141(3): 395-6, 2005 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-15781686
18.
Poor autologous mobilization status does not impact on hematological recovery but affects outcome after allogeneic stem cell transplant for lymphoma and myeloma.
Leuk Lymphoma
; 54(2): 417-20, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22702654